ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Common Stock
ExpreS2ion Biotech Holding AB
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Common Stock
kr15.7m
|
CAGR 3-Years
55%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Common Stock
kr41.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Common Stock
kr28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Common Stock
kr196m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Common Stock?
Common Stock
15.7m
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Common Stock amounts to 15.7m SEK.
What is ExpreS2ion Biotech Holding AB's Common Stock growth rate?
Common Stock CAGR 5Y
39%
Over the last year, the Common Stock growth was 33%. The average annual Common Stock growth rates for ExpreS2ion Biotech Holding AB have been 55% over the past three years , 39% over the past five years .
